Showing 2391-2400 of 2527 results for "".
- Retinal Layer Thinning in MS Advances With Disease Progressionhttps://modernod.com/news/retinal-layer-thinning-in-ms-advances-with-disease-progression/2479588/People with progressive multiple sclerosis (MS) show accelerated atrophy in inner and outer nuclear layers of the retina compared to those without the disease, offering important new pieces of the puzzle in understanding the changes that occur as MS advances, researchers say, according to a Medsc
- New Data From Alcon Shows that Compliant Contact Lens Wear Can Improve Practice Outcomeshttps://modernod.com/news/new-data-from-alcon-shows-that-compliant-contact-lens-wear-can-improve-practice-outcomes/2479590/Alcon unveiled new data from its Power of One 2.0 Program showing how patient compliance with daily and monthly contact lens replacement schedules can significantly improve patient and practice outcomes. The Power of One Program is a contact lens strategy centered on 1-day and 1-month contact len
- Roche Acquires Spark Therapeutics in $4.8 Billion Dealhttps://modernod.com/news/roche-acquires-spark-therapeutics-in-4-3-billion-deal/2476268/Swiss pharma giant Roche acquired and Philadelphia-based gene therapy company Spark Therapeutics in an all cash transaction worth $4.8 billion, or $114.50 per share. The merger has been unanimously approved by the boards of Spark Therap
- EyeBrain Medical and IDOC Announce Partnership to Bring Neurolens to IDOC Independent Optometristshttps://modernod.com/news/eyebrain-medical-and-idoc-announce-partnership-to-bring-neurolens-to-idoc-independent-optometrists/2476270/IDOC and eyeBrain Medical announced a multiyear partnership to bring neurolens prescription lenses to all IDOC members across the United States. Neurolenses are the first and only prescription lenses that add a contoured prism to bring the eyes into alignment. Contoured prisms have been shown in
- Allergan Responds to Public Shareholder Letterhttps://modernod.com/news/allergan-responds-to-public-shareholder-letter/2476274/Allergan issued the following statement from its Board of Directors in response to a public shareholder letter from Appaloosa hedge fund manager David Tepper earlier this week that stated the drugmaker should consider a merger or selling itself if it is “unable or unwilling to hold manageme
- Essilor Vision Foundation Collaborates With Government of Maharashtra to Support a Free Vision Care Program for 2.5 Million Children in Needhttps://modernod.com/news/essilor-vision-foundation-collaborates-with-government-of-maharashtra-to-support-a-free-vision-care-program-for-2-5-million-children-in-need/2476283/Essilor Vision Foundation has announced the support of the program ‘Blindness Free Maharashtra’ launched by the Government of Maharashtra in collaboration with the not-for-profit organization Ratna Nidhi Trust. Through this initiative, approximately 2.5 million children from underserv
- Diabetes Eye Exam Frequency in US Is ‘Alarmingly Low’https://modernod.com/news/diabetes-eye-exam-frequency-in-us-is-alarmingly-low/2476288/The frequency of eye exams among insured patients with type 1 and type 2 diabetes in the United States is “alarmingly low,” new research indicates, as reported in Medscape. Findings from an analysis of nationwide IBM Wa
- EU-5 Ophthalmic Market Will Top $10 Billion in 2023https://modernod.com/news/eu-5-ophthalmic-market-will-top-10-billion-in-2023/2476311/Market Scope expects growing demand for retinal pharmaceuticals to help manufacturers’ ophthalmic revenues top $10 billion in 2023 in the five largest economies of the European Union. The ophthalmic markets in France, Germany, Italy, Spain, and the UK––the five countries that made up
- Conditions Treated With Cannabis Often Lack Good Evidencehttps://modernod.com/news/conditions-treated-with-cannabis-often-lack-good-evidence/2476312/Many conditions that are considered qualifying conditions for cannabis use under state laws have no or insufficient evidence of efficacy, and some have evidence of inefficacy, according to an analysis published online F
- Avedro Launches Initial Public Offeringhttps://modernod.com/news/avedro-launches-initial-public-offering/2476317/Avedro announced that it has commenced an initial public offering of 5 million shares of common stock. The initial public offering price is currently estimated to be between $14 and $16 per share. Avedro expects to grant the underwriters a 30-day option to purchase up to an additional 750,000 sha